- OneChain’s CD22 CAR technology and NanoCell’s non-viral, DNA-based in vivo CAR-T platform will be utilized to develop innovative treatment options.
PA, USA Wayne and Barcelona, Spain, – May 16 2024, — OneChain Immunotherapeutics S.L. (OneChain) and NanoCell Therapeutics Inc. (NanoCell), announced today a strategic collaboration to develop a novel in vivo CAR-T therapy targeting B-cell lymphomas. This partnership combines OneChain’s advanced CD22 CAR technology with NanoCell’s innovative in vivo CAR-T technology platform, opening a new course for treatment in this disease area with persisting unmet need.
NanoCell’s non-viral, DNA-based CAR-T technology platform has demonstrated compelling results in pre-clinical proof of concept studies, durable CAR-T expression and robust tumor control. This new approach offers a viable alternative to conventional viral methods, potentially establishing a new standard in the field.
OneChain’s proprietary CD22 CAR molecule was developed and optimized by Professor Pablo Menendez, founder of OneChain and Professor at the Josep Carreras Institute for Leukemia. Preclinical validation of this CD22 CAR has been published in multiple peer-reviewed academic journals1.
“Partnering with NanoCell allows us to integrate our CD22 CAR with their innovative in vivo CAR-T technology, aiming to enhance treatment options for B-cell lymphoma”, said Stefanos Theoharis, CEO of OneChain Immunotherapeutics.
“We look forward to collaborating with OneChain Immunotherapeutics, and potentially offering innovative treatments beyond traditional CD19 therapies for patients with B-cell malignancies”, added Maurts Geerlings, CEO of NanoCell Therapeutics.
To learn more about our work and stay updated about our latest developments, please visit our websites at https://www.onechaintx.com/ and http://www.nanocelltx.com.
About OneChain Immunotherapeutics
OneChain Immunotherapeutics was founded in June 2020 by the Josep Carreras Leukaemia Research Institute, ICREA, and Dr. Pablo Menéndez. It is currently supported by a group of partners including the Josep Carreras Leukemia Foundation, venture capital entities Invivo Partners, Nara Capital, and Clave Capital, and the Center for Technological Development and Innovation (CDTI). The company, with headquarters at the Barcelona Science Park, focuses on developing treatments based on immunotherapy for malignant neoplasms. More information: https://www.onechaintx.com/
About NanoCell Therapeutics, Inc.
NanoCell Therapeutics is a privately held, transatlantic biotechnology company with locations in Wayne, Pennsylvania, and Utrecht, the Netherlands. We are dedicated to pioneering transformative in-vivo cell engineering through our non-viral, DNA-based gene therapy platform, primarily targeting oncology and autoimmune diseases. NanoCell’s advanced technology platform aims to evolve and enhance traditional adoptive cell therapy methods into advanced in-vivo treatments. Our objective is to streamline the overall treatment process, bolstering patient access, potential clinical benefits, and cost-effective manufacturing.
OneChain Immunotherapeutics S.L. | Communication and press office
Telephone | +34 913766458
E: press@scienseed.com
NanoCell Therapeutics Inc. | Investor Relations & Media
A. Lindman, MBA | T: +31 (0) 70 3643095
E: contact@nanocelltx.com
1Velasco- Hernandez T, Zanetti SR, Roca- Ho H, et al. Efficient elimination of primary B- ALL cells in vitro and in vivo using a novel 4- 1BB- based CAR targeting a membrane-distal CD22 epitope. Journal for ImmunoTherapy of Cancer 2020;8:e000896. doi: 10.1136/jitc-2020-000896.
Wayne, PA – March 19, 2024 — NanoCell Therapeutics, Inc. (“NanoCell”), a company developing in-vivo cell engineering solutions based on its proprietary non-viral, DNA-based gene therapy platform, today announced the appointment of Charles F. Albright, Ph.D., to its Scientific Advisory Board.